{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:36:51Z","timestamp":1760146611140,"version":"build-2065373602"},"reference-count":66,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the accumulation of abnormal plasma cells in the bone marrow. Mesenchymal stem cells (MSCs) and reticulated platelets (RPs) have been implicated in the pathogenesis of MM. This narrative review aims to explore the role of MSCs and RPs in the pathophysiology of MM, particularly their clinical use as possible variables of prognostic value in this hematologic neoplasia. The interaction between MSCs and MM cells within the bone marrow microenvironment supports MM cell survival, proliferation, and drug resistance. MSCs contribute to the development and maintenance of MM through the secretion of various factors, including cytokines, chemokines, and growth factors. Moreover, RPs, young and highly reactive platelets, have been implicated in promoting angiogenesis, tumor growth, and metastasis in MM. Several studies show that cells such as MSCs and platelets participate actively in the biology of the disease. Still, in clinical practice, they are not considered part of evaluating affected patients. In this review, we explore the possibility of including the evaluation of MSCs and PRs in the clinical practice for patients with MM as part of the strategies to improve the outcomes of this disease.<\/jats:p>","DOI":"10.3390\/hematolrep16040070","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:25:33Z","timestamp":1732533933000},"page":"732-741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5802-8327","authenticated-orcid":false,"given":"Cristian Alejandro","family":"Mera Aza\u00edn","sequence":"first","affiliation":[{"name":"Grupo Inmunobiolog\u00eda y Biolog\u00eda Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogot\u00e1 110111, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Leandro","family":"Vargas Pasquel","sequence":"additional","affiliation":[{"name":"Grupo Inmunobiolog\u00eda y Biolog\u00eda Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogot\u00e1 110111, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9291","authenticated-orcid":false,"given":"Sandra Milena","family":"Quijano G\u00f3mez","sequence":"additional","affiliation":[{"name":"Grupo Inmunobiolog\u00eda y Biolog\u00eda Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogot\u00e1 110111, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-9367","authenticated-orcid":false,"given":"Viviana Marcela","family":"Rodr\u00edguez-Pardo","sequence":"additional","affiliation":[{"name":"Grupo Inmunobiolog\u00eda y Biolog\u00eda Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogot\u00e1 110111, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities\u2014Evolution in diagnosis and classification","volume":"482","author":"Fend","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_4","first-page":"63","article-title":"Multiple myeloma etiology and treatment","volume":"6","author":"Sadaf","year":"2022","journal-title":"J. Transl. Genet. Genom."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1245\/s10434-022-12151-6","article-title":"GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists","volume":"29","author":"Deo","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","first-page":"002140","article-title":"Hypercalcaemia, Renal Dysfunction, Anaemia, Bone Disease (CRAB Criteria): A Case of Lymphoma","volume":"7","author":"Singh","year":"2020","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi","year":"2014","journal-title":"CA A Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a031286","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple Myeloma and Bone: The Fatal Interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and Diagnosis of Multiple Myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","article-title":"Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects","volume":"18","author":"Reagan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cardona-Benavides, I.J., de Ram\u00f3n, C., and Guti\u00e9rrez, N.C. (2021). Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 10.","DOI":"10.3390\/cells10020336"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-136222","article-title":"Cytogenetic Changes in Multiple Myeloma Timeline: A Tertiary Center\u2019s Experience","volume":"136","author":"Ramo","year":"2020","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e22341","DOI":"10.1096\/fj.202200354","article-title":"Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target","volume":"36","author":"Luo","year":"2022","journal-title":"FASEB J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00018-020-03600-0","article-title":"Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: Implications for further clinical uses","volume":"78","author":"Costa","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1042\/BSR20150025","article-title":"Human mesenchymal stem cells\u2013current trends and future prospective","volume":"35","author":"Ullah","year":"2015","journal-title":"Biosci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcyt.2023.04.005","article-title":"An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization\/Technical Committee 276 Biobanking Standards for bone marrow-MSCs and umbilical cord tissue\u2013derived MSCs for research purposes","volume":"25","author":"Viswanathan","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e10088","DOI":"10.1371\/journal.pone.0010088","article-title":"A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype","volume":"5","author":"Waterman","year":"2010","journal-title":"PLoS ONE"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fu, X., Liu, G., Halim, A., Ju, Y., Luo, Q., and Song, G. (2019). Mesenchymal Stem Cell Migration and Tissue Repair. Cells, 8.","DOI":"10.3390\/cells8080784"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/stcltm\/szad043","article-title":"Orchestration of Mesenchymal Stem\/Stromal Cells and Inflammation During Wound Healing","volume":"12","author":"Zhu","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wu, S., Sun, S., Fu, W., Yang, Z., Yao, H., and Zhang, Z. (2024). The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040743"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: A therapeutical tool or target?","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4252\/wjsc.v6.i3.322","article-title":"Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics","volume":"6","author":"Miguel","year":"2014","journal-title":"World J. Stem Cells"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2017.07.002","article-title":"Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-\u03baB signaling","volume":"60","author":"Yang","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12935-024-03308-2","article-title":"Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma","volume":"24","author":"Lu","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"862524","DOI":"10.3389\/fcell.2022.862524","article-title":"Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2","volume":"10","author":"Gu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wang, L., Yi, W., Ma, L., Lecea, E., Hazlehurst, L.A., Adjeroh, D.A., and Hu, G. (2023). Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers, 15.","DOI":"10.3390\/cancers15215148"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.02.005","article-title":"Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway","volume":"57","author":"Zhao","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-018-0545-6","article-title":"Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells","volume":"9","author":"Guo","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2019.01.003","article-title":"BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner","volume":"207","author":"Ibraheem","year":"2019","journal-title":"Transl. Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Matula, Z., Mikala, G., Luk\u00e1csi, S., Matk\u00f3, J., Kov\u00e1cs, T., Monostori, \u00c9., Uher, F., and V\u00e1lyi-Nagy, I. (2021). Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells. Cancers, 13.","DOI":"10.3390\/cancers13143461"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fendo.2018.00218","article-title":"Soluble and Cell\u2013Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"9","author":"Farrell","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41389-022-00380-z","article-title":"CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment","volume":"11","author":"Giallongo","year":"2022","journal-title":"Oncogenesis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41388-018-0359-0","article-title":"Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaay8203","DOI":"10.1126\/scisignal.aay8203","article-title":"Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells","volume":"13","author":"Liu","year":"2020","journal-title":"Sci. Signal"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.5114\/aoms.2017.71065","article-title":"Impact of connexin 43 coupling on survival and migration of multiple myeloma cells","volume":"13","author":"Zhang","year":"2017","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2014.913289","article-title":"Up-regulation of connexin-43 expression in bone marrow mesenchymal stem cells plays a crucial role in adhesion and migration of multiple myeloma cells","volume":"56","author":"Zhang","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbrc.2020.10.093","article-title":"Myeloma cells self-promote migration by regulating TAB1-driven TIMP-1 expression in mesenchymal stem cells","volume":"534","author":"Rethnam","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Corpataux, N., Franke, K., Kille, A., Valina, C.M., Neumann, F.-J., and N\u00fchrenberg, T. (2020). Reticulated Platelets in Medicine: Current Evidence and Further Perspectives. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113737"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","article-title":"Platelet biology and functions: New concepts and clinical perspectives","volume":"16","author":"Heemskerk","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1055\/s-0038-1667338","article-title":"Reticulated Platelets: Changing Focus from Basics to Outcomes","volume":"118","author":"Hannawi","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11239-017-1533-x","article-title":"Characterization of surface antigens of reticulated immature platelets","volume":"44","author":"Lador","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.29847","article-title":"Platelets in cancer metastasis: To help the \u201cvillain\u201d to do evil","volume":"138","author":"Li","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1002\/mco2.350","article-title":"The role of platelets in the regulation of tumor growth and metastasis: The mechanisms and targeted therapy","volume":"4","author":"Liao","year":"2023","journal-title":"MedComm"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-Derived Nucleotides Promote Tumor-Cell Transendothelial Migration and Metastasis via P2Y2 Receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.celrep.2018.03.092","article-title":"Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration","volume":"23","author":"Ward","year":"2018","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"919495","DOI":"10.3389\/fcvm.2022.919495","article-title":"Patients With Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile","volume":"9","author":"Li","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.16774","article-title":"Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance","volume":"192","author":"Gilligan","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2012-10-461798","article-title":"Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression","volume":"121","author":"Gilje","year":"2013","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2264940","DOI":"10.1080\/09537104.2023.2264940","article-title":"Multiple myeloma and its treatment contribute to increased platelet reactivity","volume":"34","author":"Mitchell","year":"2023","journal-title":"Platelets"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-021-01101-6","article-title":"CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients","volume":"14","author":"Ke","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-140821","article-title":"Prospective Study Reveals Increased Platelet Function Associated with Multiple Myeloma and Its Treatment","volume":"136","author":"Khan","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1002\/mco2.663","article-title":"The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics","volume":"5","author":"Tang","year":"2024","journal-title":"MedComm"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","article-title":"Mesenchymal stem cells: Key players in cancer progression","volume":"16","author":"Ridge","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., and Gasque, P. (2023). The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713511"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/ijc.31727","article-title":"Detection of endogenously circulating mesenchymal stem cells in human cancer patients","volume":"143","author":"Houthuijzen","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"103416","DOI":"10.1016\/j.critrevonc.2021.103416","article-title":"Bone marrow\/bone pre-metastatic niche for breast cancer cells colonization: The role of mesenchymal stromal cells","volume":"164","author":"Sanmartin","year":"2021","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40164-024-00532-4","article-title":"Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression","volume":"13","author":"Zhang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.clml.2024.05.020","article-title":"Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients treated with novel therapies","volume":"24","author":"Charalampous","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"65. Mai, E.K., Hielscher, T., Bertsch, U., Salwender, H.J., Zweegman, S., Raab, M.S., Munder, M., Pantani, L., Mancuso, K., and Brossart, P. (2024). Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: Data from five randomized, controlled, phase III trials in 3700 patients. Leukemia, 38, 640\u2013647.","DOI":"10.1038\/s41375-023-02105-6"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1421854","DOI":"10.3389\/fimmu.2024.1421854","article-title":"Advances and clinical challenges of mesenchymal stem cell therapy","volume":"15","author":"Mei","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/70\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:38:03Z","timestamp":1760114283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["hematolrep16040070"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16040070","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2024,11,23]]}}}